Tyme Technologies, Inc. (TYME): Price and Financial Metrics


Tyme Technologies, Inc. (TYME)

Today's Latest Price: $1.78 USD

0.13 (-6.81%)

Updated Jan 27 4:00pm

Add TYME to Watchlist
Sign Up

Overall POWR Rating

Sign Up to See Ratings...FREE!

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

TYME Stock Price Chart Interactive Chart >

Price chart for TYME

TYME Price/Volume Stats

Current price $1.78 52-week high $2.50
Prev. close $1.91 52-week low $0.85
Day low $1.76 Volume 1,906,750
Day high $1.96 Avg. volume 3,112,856
50-day MA $1.33 Dividend yield N/A
200-day MA $1.24 Market Cap 231.71M

Tyme Technologies, Inc. (TYME) Company Bio

Tyme Technologies, Inc., a clinical-stage pharmaceutical company, focuses on the discovery and development of cancer therapeutics for various oncology indications. It is developing SM-88, a combination therapy in Phase II development for prostate cancer. The company was founded in 2011 and is based in New York, New York.

Most Popular Stories View All

• #1 Ingredient for Picking the Best Stocks

• Is General Motors the Next Tesla?

• 2 Stocks That Could be Acquisition Targets in 2021: DropBox, Yelp

• 3 "Strong Buy" Tech Stocks with PE Ratios Under 15

• Forget Alibaba, Buy These 4 Asian E-Commerce Stocks Instead

View All Top Stories

TYME Latest News Stream

Event/Time News Detail
Loading, please wait...
View All TYME News

TYME Latest Social Stream

Loading social stream, please wait...

View Full TYME Social Stream

Latest TYME News From Around the Web

Below are the latest news stories about Tyme Technologies Inc that investors may wish to consider to help them evaluate TYME as an investment opportunity.

SemiLEDs to Announce Fiscal First Quarter 2021 Financial Results on Friday, January 8, 2021

SemiLEDs Corporation (NASDAQ:LEDS), will report financial results for the 2021 fiscal First quarter ended November 30, 2020 after market close on Friday, January 08, 2021.

Yahoo | January 6, 2021

We're Keeping An Eye On Tyme Technologies' (NASDAQ:TYME) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Yahoo | December 15, 2020

TYME Builds Leadership Team with Announcement of New CEO

Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTsTM), announced that, effective November 24, 2020, Steve Hoffman will remain in the role of Chairman of the board of directors and continue as the Company’s Chief Science Officer, after a successful tenure as Chief Executive Officer since 2015. Richie Cunningham, former Icagen CEO and Boehringer Ingelheim executive, has been appointed as TYME’s next Chief Executive Officer.

Yahoo | November 30, 2020

Tyme Technologies (NASDAQ:TYME) Upgraded to “Buy” at Zacks Investment Research

Zacks Investment Research upgraded shares of Tyme Technologies (NASDAQ:TYME) from a hold rating to a buy rating in a research note published on Thursday morning, Zacks.com reports. They currently have $1.00 price objective on the stock. According to Zacks, “Tyme Technologies, Inc. is a pharmaceutical company. The company is focused on creating medicines which specialize […]

Transcript Daily | November 20, 2020

TYME Provides Business Update and Announces Second Quarter Fiscal 2021 Financial and Operating Results

Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced financial and operating results for its second quarter ended September 30, 2020. During the quarter, TYME revealed a potential new therapeutic approach in the fight against COVID-19; was granted orphan drug designation for SM-88 as a potential treatment for patients with pancreatic cancer; expanded its body of peer-reviewed publications on SM-88 and clinical significance in treating advanced cancers; continued enrolling patients in multiple studies including, second and third-line pancreatic cancer trials and the HopES Sarcoma Phase II trial; advanced planning for clinical trials in metastatic breast cancer and hematological cancers; and continued on...

Yahoo | November 12, 2020

Read More 'TYME' Stories Here

TYME Price Returns

1-mo 60.36%
3-mo 94.75%
6-mo 49.58%
1-year 14.10%
3-year -64.47%
5-year -83.82%
YTD 45.90%
2020 -12.86%
2019 -62.06%
2018 -42.16%
2017 70.13%
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.73 seconds.